bl-arc001
mAbexperimentalADC
Clinical trial activity
2 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Dec 31, 2025 (NCT07274852)
Timeline
2020s
- Jan 1, 2025
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
EGFR inhibitor
Chemistry & pharmacology
- Payload
- 177-lutetium
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07232407 | Phase 1 | Dec 31, 2025 | Baili Pharmaceutical Group |
| NCT07274852 | Phase 1 | Dec 31, 2025 | Baili Pharmaceutical Group |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Baili Pharmaceutical Group | For profit | 2 | 2 | 1 | 2025 |
1 organizations
Page 1 / 1